Elora Gupta

633 total citations
9 papers, 357 citations indexed

About

Elora Gupta is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Elora Gupta has authored 9 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Pharmacology. Recurrent topics in Elora Gupta's work include Cancer therapeutics and mechanisms (4 papers), Peptidase Inhibition and Analysis (2 papers) and Protease and Inhibitor Mechanisms (2 papers). Elora Gupta is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Peptidase Inhibition and Analysis (2 papers) and Protease and Inhibitor Mechanisms (2 papers). Elora Gupta collaborates with scholars based in United States, Germany and Sweden. Elora Gupta's co-authors include Eric H. Rubin, Viral Vyas, A. H. Cornfield, T. S. Ravikumar, John Bird, Pamela A. Trail, Joseph Fargnoli, Susan Goodin, Maria Jure‐Kunkel and Arris J. Henderson and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of the New York Academy of Sciences.

In The Last Decade

Elora Gupta

9 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elora Gupta United States	9	216	203	101	50	35	9	357
Timothy Korbut United States	10	183 0.8×	206 1.0×	96 1.0×	42 0.8×	46 1.3×	16	396
Jean-Pierre Bizzari France	14	267 1.2×	288 1.4×	51 0.5×	37 0.7×	95 2.7×	24	515
Na Qiao United States	12	192 0.9×	203 1.0×	47 0.5×	33 0.7×	55 1.6×	19	475
Scott L. Young United States	4	109 0.5×	222 1.1×	74 0.7×	28 0.6×	33 0.9×	6	425
Samira Syed United States	11	151 0.7×	122 0.6×	94 0.9×	22 0.4×	55 1.6×	37	390
Frances C. Nelson United States	11	178 0.8×	200 1.0×	164 1.6×	41 0.8×	7 0.2×	12	428
Leeona Galligan United Kingdom	8	264 1.2×	384 1.9×	87 0.9×	19 0.4×	73 2.1×	9	591
Luca Ricotti Italy	11	226 1.0×	189 0.9×	81 0.8×	21 0.4×	102 2.9×	22	440
Batool Shannan Germany	8	330 1.5×	258 1.3×	79 0.8×	11 0.2×	79 2.3×	11	544
Susan Flamm Honig United States	7	190 0.9×	173 0.9×	107 1.1×	21 0.4×	38 1.1×	9	399

Countries citing papers authored by Elora Gupta

Since Specialization

Citations

This map shows the geographic impact of Elora Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elora Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elora Gupta more than expected).

Fields of papers citing papers by Elora Gupta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elora Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elora Gupta. The network helps show where Elora Gupta may publish in the future.

Co-authorship network of co-authors of Elora Gupta

This figure shows the co-authorship network connecting the top 25 collaborators of Elora Gupta. A scholar is included among the top collaborators of Elora Gupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elora Gupta. Elora Gupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Mohan, Puneet, et al.. (2014). Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Annals of the New York Academy of Sciences. 1329(1). 93–106. 15 indexed citations

Rizvi, Naiyer A., Jeffrey S. Humphrey, Elizabeth Ness, et al.. (2004). A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer. Clinical Cancer Research. 10(6). 1963–1970. 47 indexed citations

Plummer, Ruth, Michele Ghielmini, Paula Calvert, et al.. (2002). Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.. PubMed. 8(9). 2788–97. 21 indexed citations

Hidalgo, Manuel, Cheryl Aylesworth, Lisa A. Hammond, et al.. (2001). Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel. Journal of Clinical Oncology. 19(9). 2493–2503. 33 indexed citations

Naglich, Joseph G., Maria Jure‐Kunkel, Elora Gupta, et al.. (2001). Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.. PubMed. 61(23). 8480–5. 89 indexed citations

Gupta, Elora, et al.. (2000). Pharmacokinetics of Orally Administered Camptothecins. Annals of the New York Academy of Sciences. 922(1). 195–204. 26 indexed citations

Verschraegen, Claire F., Elora Gupta, Evelyne M. Loyer, et al.. (1999). A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anti-Cancer Drugs. 10(4). 375–384. 55 indexed citations

Vyas, Viral, A. H. Cornfield, Susan Goodin, et al.. (1999). In vitro activation of irinotecan to SN-38 by human liver and intestine.. PubMed. 19(3A). 2067–71. 50 indexed citations

Vyas, Viral, Ahamed Saleem, A. H. Cornfield, et al.. (1998). High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin. Journal of Chromatography B Biomedical Sciences and Applications. 707(1-2). 227–233. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact